Visão geral da empresa
YD Bio Limited operates as a biopharmaceutical enterprise headquartered in Taipei, Taiwan, with a primary focus on blood-based cancer detection technologies. The company is dedicated to the development of stem cell- and exosome-based therapeutics aimed at transforming the treatment landscape for a spectrum of diseases characterized by unmet medical needs. Within the broader financial landscape, YD Bio is classified under the Healthcare sector and specifically within the Biotechnology industry, positioning it as an entity focused on long-term research and potential breakthrough therapies rather than immediate consumer goods. The company currently maintains a market capitalization of $406.20M and reported annual revenue of $510,360 over the trailing twelve months, while specific employee count data is not publicly disclosed. These valuation and revenue figures indicate that the company is in an early-stage growth phase typical for biotechnology firms, where significant capital is often required to advance clinical trials and regulatory approvals before achieving substantial profitability or scaling operations.
Saúde financeira
The financial statements for YD Bio Ltd reveal a revenue of $510,360, a net income of $-1,411,559, and an EBITDA of $-1,357,195, highlighting a substantial operational deficit relative to top-line performance. The significant gap between the reported revenue of $510,360 and the net loss of $-1,411,559 underscores a cost structure where operating expenses, likely driven by R&D expenditures and clinical trial costs, far exceed current sales generation. The company's free cash flow stands at $-3,875,569, which indicates a heavy reliance on external financing to fund ongoing research and development activities rather than generating internal cash reserves for reinvestment. Profitability metrics further illustrate this challenge, with a gross margin of 30.4%, an operating margin of -444.6%, and a profit margin of -276.6%, suggesting that while the core product sales are somewhat efficient, the overall business model has not yet achieved operational breakeven. Liquidity analysis shows the company holds $3.13M in cash against a debt obligation of $22,265, resulting in a debt-to-equity ratio of 0.34, which suggests a relatively conservative balance sheet structure with minimal leverage. Furthermore, the current ratio is reported at 13.18, indicating an extremely strong position in short-term liquidity where current assets significantly outweigh current liabilities. Return on equity is recorded at -42.7% and return on assets at -25.4%, metrics that reveal that management has not yet generated positive returns on the capital invested by shareholders or the asset base.
Avaliação de valorização
Valuation multiples for YD Bio Ltd present a mixed picture typical of pre-profitability biotechnology firms, as the trailing P/E ratio is N/A due to the lack of positive earnings and the forward P/E is also N/A, implying that earnings trajectory expectations remain uncertain until profitability is achieved. The price-to-book ratio is 1.26, indicating that the market values the company's equity at a slight premium of 26% over its book value, which may reflect intangible assets such as intellectual property or potential future value from its pipeline. Alternative valuation metrics provide further context, with a price-to-sales ratio of 795.91 and an EV/EBITDA of -3.83, suggesting that investors are pricing the stock based on revenue growth potential and asset backing rather than current earnings power. Regarding trading ranges, the 52-week high is $25.00 and the 52-week low is $5.30, meaning the current market price sits at a level that requires specific calculation relative to this range to determine exact percentage distance from highs and lows. The stock exhibits a beta of 0.22, which indicates that the price volatility of YD Bio is significantly lower than that of the broader market, suggesting lower systematic risk but potentially lower upside potential in rising market environments.
Growth & Income
Revenue growth year-over-year is reported at 95.6%, demonstrating aggressive expansion in sales, while earnings growth is N/A due to the company's continued net losses, implying that top-line revenue expansion is occurring without corresponding improvement in profitability. As a non-dividend payer, YD Bio maintains a dividend yield of N/A and a payout ratio of 0.0%, which indicates that the company retains all of its earnings to fund operations and research rather than distributing income to shareholders. The absence of dividend payments aligns with the strategic necessity for biotechnology companies to reinvest every available dollar into clinical development and manufacturing scale-up to achieve commercial viability. Overall, the company's growth and income profile is characterized by high revenue expansion coupled with significant cash burn and a complete absence of current income distribution to investors.